The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Serologic, radiographic, and tissue-based markers associated with major pathologic response after treatment with neoadjuvant immunotherapy in patients with resectable hepatocellular carcinoma.
 
Michael Brian LaPelusa
No Relationships to Disclose
 
Shadi Chamseddine
No Relationships to Disclose
 
Lianchun Xiao
No Relationships to Disclose
 
Elshad Hasanov
No Relationships to Disclose
 
Priya Bhosale
No Relationships to Disclose
 
Yehia I. Abugabal
No Relationships to Disclose
 
Betul Gok Yavuz
No Relationships to Disclose
 
Shalini S. Yadav
No Relationships to Disclose
 
Hop Sanderson Tran Cao
No Relationships to Disclose
 
Li Xu
No Relationships to Disclose
 
Zishuo Ian Hu
No Relationships to Disclose
 
Sunyoung S. Lee
No Relationships to Disclose
 
Divya Sakamuri
No Relationships to Disclose
 
Michael A. Curran
Leadership - ImmunoGenesis
Stock and Other Ownership Interests - Agenus (I); ImmunoGenesis; ImmunOs Therapeutics; Sana Biotechnology (I)
Consulting or Advisory Role - Adagene; Agenus; Alligator Bioscience; Amunix; Aptevo Therapeutics; AstraZeneca/MedImmune; ImmunOs Therapeutics; Nurix; OncoResponse; Tentarix Biotherapeutics; Xencor
Research Funding - ImmunoGenesis
Patents, Royalties, Other Intellectual Property - The Regents of the University of California, James Allison and Michael Curran. Methods and Composition for Localized Secretion of Anti-CTLA-4 Antibodies, United States, US 9,868,961 B2.; The University of Texas MD Anderson Cancer Center, Philip Jones, Maria Emilia DiFrancesco, Michael A. Curran. Cyclic Dinucleotides as Agonists of Stimulator of Interferon Gene Dependent Signaling, United States, 62/461,642.; The University of Texas, MD Anderson Cancer Center, Michael A. Curran, Carlo Toniatti, Ashvin R. Jaiswal, Dongxing Zha, and Voo Kui. Dual specificity antibodies which bind both PD-L1 and PD-L2 and prevent their binding to PD-1, United States, PCT/US2019/0
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; ImmunOs Therapeutics
 
Sonali Jindal
No Relationships to Disclose
 
Gabriel Dan Duda
Honoraria - Bayer; Simcere; Surface Oncology
Consulting or Advisory Role - Innocrin Pharma
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Surface Oncology (Inst)
 
Padmanee Sharma
Stock and Other Ownership Interests - Achelois Oncology; Achelois Oncology (I); Adaptive Biotechnologies; Adaptive Biotechnologies (I); Affini-T Therapeutics; Affini-T Therapeutics (I); Apricity Health; Apricity Health (I); BioAtla; BioAtla (I); BioNTech; BioNTech (I); Candel Therapeutics; Candel Therapeutics (I); Catalio; Codiak Biosciences; Codiak Biosciences (I); Dragonfly Therapeutics; Dragonfly Therapeutics (I); Earli; Earli (I); Enable Medicine; Enable Medicine (I); Glympse Bio; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; InterVenn Biosciences; InterVenn Biosciences (I); JSL Health; Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Oncolytics; PBM Capital; PBM Capital (I); Phenomic AI; Phenomic AI (I); Polaris; Polaris (I); Sporos Bio; Time Bioventures; Trained Therapeutix Discovery; Trained Therapeutix Discovery (I); Two Bear Capital; Two Bear Capital (I)
Consulting or Advisory Role - Achelois Oncology; Achelois Oncology (I); Affini-T Therapeutics; Apricity Health; Apricity Health (I); Asher Biotherapeutics; BioAtla; BioAtla (I); C-Reveal Therapeutics; Candel Therapeutics; Candel Therapeutics (I); Carisma Therapeutics; Catalio; Codiak Biosciences; Codiak Biosciences (I); Dragonfly Therapeutics; Dragonfly Therapeutics (I); Earli; Earli (I); Enable Medicine; Enable Medicine (I); Glympse Bio; Henlius; Hummingbird; Hummingbird (I); ImaginAb; ImaginAb (I); Infinity Pharmaceuticals; InterVenn Biosciences; Lava Therapeutics; Lava Therapeutics (I); Lytix Biopharma; Lytix Biopharma (I); Marker Therapeutics; Marker Therapeutics (I); Oncolytics; PBM Capital; PBM Capital (I); Phenomic AI; Phenomic AI (I); Polaris; Polaris (I); Trained Therapeutix Discovery; Trained Therapeutix Discovery (I); Two Bear Capital; Two Bear Capital (I); Xilis
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)
 
Aliya Qayyum
No Relationships to Disclose
 
Ahmed Omar Kaseb
Honoraria - AstraZeneca; Bayer Health; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca; Bayer Health; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
Research Funding - Adaptimmune (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Hengrui Pharmaceutical (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck